Xiaojin Wu

Dr. Xiaojin Wu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2012 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
YWYu Wang
Yu Wang
DLDai‐Hong Liu
Dai‐Hong Liu
ZFZhi‐Ping Fan
Zhi‐Ping Fan
JSJing Sun
Jing Sun
XWXiaojin Wu
Xiaojin Wu
Xiaojun HuangXiaojun Huang
Xiaojun Huang

1 August 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
YXYiyu Xie
Yiyu Xie
JPJay Parekh
Jay Parekh
ZTZaixiang Tang
Zaixiang Tang
DWDepei Wu
Depei Wu
XWXiaojin Wu
Xiaojin Wu
With increase in the number of non-matched hematopoietic stem cell transplants (HSCT), there has been growth in evidence regarding factors affecting graft outcomes. One of the factors affecting graft outcomes that are currently being evaluated is anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs). We designed our study to analyze the clinical relevance of anti-HLA DSAs in patients who have undergone hematopoietic stem cell transplant at a population level by conducting a systematic review of existing literature. A comprehensive search was conducted through PUBMED, Embase, Cochrane library and Web of Science from inception to January 1, 2021. A meta-analysis was performed of the association between anti-HLA DSAs and primary graft failure with further subgroup analyses. It was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 920 eligible citations were identified out of which 15 studies were included in the final meta-analyses after application of rigorous selection criteria and independent review. A total of 2436 patients were included. Patients with anti-HLA DSAs prior to HSCT had a 7.47-fold increased risk of primary graft failure compared to patients without DSA (OR 7.47, 95%CI 4.54-12.28, p<0.001; I2= 28.91%, P = 0.1315). In subgroup and meta-regression analyses, areas, NOS, mean fluorescence intensity (MFI) cut off, primary diseases, HSCT types, graft sources, and pre-transplant desensitization did not affect the impact of anti-HLA DSAs on primary graft failure (PGF). There was no significant difference between the impact of HLA class I and II on PGF as well. We conclude that prior presence of anti-HLA DSAs had negative impact on graft outcomes in patients with haploidentical and umbilical cord blood hematopoietic stem cell transplants.

16 September 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
HGHuanle Gong
Huanle Gong
SMShoubao Ma
Shoubao Ma
JCJia Chen
Jia Chen
BYBingyu Yang
Bingyu Yang
SLShuangzhu Liu
Shuangzhu Liu
DWDepei Wu
Depei Wu
Interleukin 27 (IL-27), a heterodimeric cytokine composed of Epstein-Barr virus-induced 3 and p28, is a pleiotropic cytokine with both pro-and anti-inflammatory properties. However, the precise role of IL-27 in acute graft-versus-host disease is not yet fully understood. In this study, utilizing mice with IL-27 p28 deficiency in dendritic cells (DCs), we demonstrated that IL-27 p28 deficiency resulted in impaired Treg cell function and enhanced effector T cell responses, corresponding to aggravated aGVHD in mice. In addition, using single-cell RNA sequencing, we found that loss of IL-27 p28 impaired Treg cell generation and promoted IL-1R2+TIGIT+ pathogenic CD4+ T cells in the thymus at a steady state. Mechanistically, IL-27 p28 deficiency promoted STAT1 phosphorylation and Th1 cell responses, leading to the inhibition of Treg cell differentiation and function. Finally, patients with high levels of IL-27 p28 in serum showed a substantially decreased occurrence of grade II-IV aGVHD and more favorable overall survival than those with low levels of IL-27 p28. Thus, our results suggest a protective role of DC-derived IL-27 p28 in the pathogenesis of aGVHD through modulation of the Treg/Teff cell balance during thymic development. IL-27 p28 may be a valuable marker for predicting aGVHD development after transplantation in humans.

3 August 2024 in Biomarker Research
Verified
Journal Article
Open access
PDF file
CSChao Sui
Chao Sui
HWHeqing Wu
Heqing Wu
XLXinxin Li
Xinxin Li
YWYuhang Wang
Yuhang Wang
JWJiaqi Wei
Jiaqi Wei
XWXiaojin Wu
Xiaojin Wu
Cancer immunotherapy has sparked a wave of cancer research, driven by recent successful proof-of-concept clinical trials. However, barriers are emerging during its rapid development, including broad adverse effects, a lack of reliable biomarkers, tumor relapses, and drug resistance. Integration of nanomedicine may ameliorate current cancer immunotherapy. Ultra-large surface-to-volume ratio, extremely small size, and easy modification surface of nanoparticles enable them to selectively detect cells and kill cancer cells in vivo. Exciting synergistic applications of the two approaches have emerged in treating various cancers at the intersection of cancer immunotherapy and cancer nanomedicine, indicating the potential that the combination of these two therapeutic modalities can lead to new paradigms in the treatment of cancer. This review discusses the status of current immunotherapy and explores the possible opportunities that the nanomedicine platform can make cancer immunotherapy more powerful and precise by synergizing the two approaches.

3 May 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
XWXiaojin Wu
Xiaojin Wu
YXYiyu Xie
Yiyu Xie
CWChang Wang
Chang Wang
YHyue han
yue han
XBXiebing Bao
Xiebing Bao
DWDepei Wu
Depei Wu
BACKGROUND. There are very few studies investigating metabolic biomarkers to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Metabolic models can provide a framework for analyzing the information-rich omics data sets in this setting. METHODS. Four hundred and fifty-six samples from one hundred and fourteen consecutive patients who underwent HSCT from January 2012 to May 2014 were collected for this study. The changes in serum metabolite levels were investigated using a gas chromatography–mass spectrometry–based metabolomics approach and underwent statistical analysis. RESULTS. Significant metabolic changes were observed on day 7. The stearic acid/palmitic acid (SA/PA) ratio was effective in the diagnosis of grade II–IV aGVHD. Multivariate analysis showed that patients with high SA/PA ratios on day 7 after HSCT were less likely to develop II–IV aGVHD than patients with low SA/PA ratios (odds ratio [OR] = 0.06, 95% CI 0.02–0.18, P < 0.001). After the adjustment for clinical characteristics, the SA/PA ratio had no significant effect on overall survival (hazard ratio [HR] = 1.95, 95% CI 0.92–4.14, P = 0.08), and patients in the high SA/PA ratio group were significantly more likely to relapse than those in the low ratio group (HR = 2.26, 95% CI 1.04–4.91, P = 0.04). CONCLUSION. Our findings suggest that the SA/PA ratio on day 7 after HSCT is an excellent biomarker to predict both aGVHD and relapse. The serum SA/PA ratio measured on day 7 after transplantation may improve risk stratification for aGVHD and relapse after allogeneic stem cell transplantation. FUNDING. National Natural Science Foundation of China (81470346, 81773361), Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Natural Science Foundation (BK20161204), Innovation Capability Development Project of Jiangsu Province (BM2015004), Jiangsu Medical Junior Talent Person award (QNRC2016707), and NIH (AI129582 and NS106170).

27 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LXLiangjing Xu
Liangjing Xu
JXJinge Xu
Jinge Xu
SMShoubao Ma
Shoubao Ma
XLXiaoli Li
Xiaoli Li
MZMingqing Zhu
Mingqing Zhu
XWXiaojin Wu
Xiaojin Wu
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Liangjing Xu1, 2, 3, 4, *, Jinge Xu1, 2, 3, 4, 5, *, Shoubao Ma2, 3, 4, *, Xiaoli Li1, 2, 3, 4, Mingqing Zhu1, 2, 3, 4, Suning Chen1, 2, 3, 4, Yue Han1, 2, 3, 4, Xiaowen Tang1, 2, 3, 4, Zhengzheng Fu1, 2, 3, 4, Huiying Qiu1, 2, 3, 4, Jianhua Yu6, Depei Wu1, 2, 3, 4 and Xiaojin Wu1, 2, 3, 4 1Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China 2Institute of Blood and Marrow Transplantation, Suzhou, China 3Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China 4Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China 5The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China 6The Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA *Co-First author Correspondence to: Depei Wu, email: wudepei@medmail.com.cn Jianhua Yu, email: Jianhua.yu@osumc.edu Xiaojin Wu, email: wuxiaojin@suda.edu.cn Keywords: Tim-3; acute leukemia; expression; chemotherapy Received: June 14, 2017 Accepted: August 17, 2017 Published: October 27, 2017 ABSTRACT T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion. Tim-3 has also been identified in various solid tumors. However, the role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) is not well understood. In this study, we aimed to explore the role of Tim-3 in patients with de novo AML, and the correlation between Tim-3 and clinicopathological prognosis. The study cohort consisted of 76 patients with de novo non-M3 AML. These patients’ bone marrow samples were collected and then bone marrow mononuclear cells (BMCs) were isolated for flow cytometry to detect Tim-3 expression on blasts. According to FAB type, 76 diagnosed AML patients included in this study were: M0 (n=2), M1 (n=16), M2 (n=20), M4 (n=20), M5 (n=16), and M6 (n=2). A positive expression (>20%) of Tim-3 was found in 87% (66/76) of patients with AML. The average percentage of Tim-3(+) blasts in these AML patients was 58.26 ± 29.23%. Moreover, the frequency of Tim-3 high expression was higher in M4 patients than that in other AML patients according to FAB type (P=0.004). Tim-3 high expression was also closely associated with inv(16) (P=0.01) and C/EBPA mutation (P=0.03). The mutations of the following six genes, i.e., FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, were independent of the Tim-3 expression. Additionally, it is more likely to find higher levels of Tim-3 in the low-risk group than in the intermediate- and high-risk groups (P=0.02). The expression of Tim-3 was positively correlated with CD13 (r=0.36, P=0.001), CD34 (r=0.41, P=0.000), and CD7 (r=0.27, P=0.02) in AML patients. AML patients with high Tim-3 expression achieved significantly high complete remission (CR) rate (P=0.01), while their Tim-3 expression significantly decreased after CR (P=0.01). Blockade of Tim-3 expression on AML blasts significantly reduced the Idarubicin (IDA)-mediated suppression of cell growth and reduction of cell apoptosis in vitro. Collectively, our study suggests that high Tim-3 expression on AML blasts could enhances chemotherapy sensitivity.